TCGA-18-3416-01A-01R-0980-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.550
- G2M_CHECKPOINT+0.500
- INTERFERON_GAMMA_RESPONSE+0.470
- MYC_TARGETS_V2+0.470
- INTERFERON_ALPHA_RESPONSE+0.460
- MTORC1_SIGNALING+0.430
- ALLOGRAFT_REJECTION+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ANGIOGENESIS-0.460
- COAGULATION-0.430
- TGF_BETA_SIGNALING-0.390
- MYOGENESIS-0.350
- APICAL_JUNCTION-0.280
- HEDGEHOG_SIGNALING-0.280
- UV_RESPONSE_DN-0.280
- NOTCH_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.926 |
| 2 | SRR8518289 | — | E | 0.914 |
| 3 | TCGA-39-5016-01A-01R-1443-07 | — | cohortSQ2 | 0.904 |
| 4 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.895 |
| 5 | SRR5088813 | — | — | 0.881 |
| 6 | TCGA-66-2758-01A-02R-0851-07 | — | cohortSQ2 | 0.877 |
| 7 | SRR6013511 | — | cohortSQ1 | 0.875 |
| 8 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.870 |
| 9 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.866 |
| 10 | TCGA-18-3419-01A-01R-0980-07 | — | cohortSQ1 | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |